|Articles|October 2, 2021
Using ML, AI and RWD to Infer HCP Specialties
Author(s)IPM.ai
Pharmaceutical sales operations teams often rely on outdated or inaccurate data when prioritizing HCP targets, limiting promotional effectiveness. By applying artificial intelligence and machine learning to real world data, pharmaceutical companies can more effectively target physicians hiding in plain sight and PCPs behaving like specialists.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
5
